Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Product sales, net	$ 1,811,386	$ 1,915,909
Cost of products sold	527,250	618,694
Gross profit	1,284,136	1,297,215
Selling, general and administrative expenses	2,785,262	2,109,050
Research and development expenses	107,480	6,346
Total operating expenses	2,892,742	2,115,396
Loss from operations	(1,608,606)	(818,181)
Other expenses	(4,210)	(2,264)
Interest income	113	1,019
Change in fair value of derivative liability		40,260
Loss before provision for income taxes and net of equity investments	(1,612,703)	(779,166)
Provision for income taxes	(250)	(4,465)
Loss before equity in net earnings (losses) of equity investments	(1,612,953)	(783,631)
Earnings from China Joint Venture		(9,564)
Net loss	(1,612,953)	(793,195)
Net loss attributable to noncontrolling interests	(12,738)	(10,443)
Net loss attributable to Milestone Scientific Inc.	$ (1,600,215)	$ (782,752)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.03)	$ (0.02)
Diluted (in dollars per share)	$ (0.03)	$ (0.02)
Weighted average shares outstanding and to be issued—
Basic (in shares)	49,730,252	40,531,762
Diluted (in shares)	49,730,252	40,531,762